CureMatch
×
  • Physicians
  • Patients
  • Employers
  • About Us
  • News
    • CureMatch News
    • Validation and Research
    • Events & Conferences
  • Contact
  • Login

CureMatch joins MetroConnect to push toward providing global cancer treatment options

CureMatch joins MetroConnect to push toward providing global cancer treatment options
Press Releases
world-trade-center-san-diego-logo

PRESS CONTACT  
Martin Culjat
858-859-2873
press@curematch.com

SAN DIEGO, CA – CureMatch is pleased to announce it has been selected to take part in MetroConnect 2017, an export assistance program run by the World Trade Center San Diego (WTC) and designed to help San Diego companies accelerate their global growth. The announcement will be made today by San Diego Mayor Kevin Faulconer and WTC San Diego.

This program will enhance CureMatch’s ability to expand and pursue international markets and expand global partnership opportunities for its cancer treatment support product. CureMatch is the only company to offer a report that guides oncologists in the selection of personalized combination therapies, using supercomputing and the latest discoveries in genomics and proteomics. CureMatch analyzes more than 4.5 million different drug combinations to find and rank the most advanced cancer treatments, customized specifically for the individual patient.

“We are honored to have been selected to join the prestigious MetroConnect program,” said CureMatch CEO Blaise Barrelet. “We are now selling our product globally, and look forward to working with the World Trade Center San Diego to help us to navigate regulations and reach new customers. The ultimate goal is to enable patients to have access to the most advanced personalized cancer treatment, no matter what part of the world they are in.”

As the flagship export assistance program of World Trade Center San Diego, MetroConnect seeks to cultivate a pipeline of export-ready firms to elevate San Diego’s global reach. Now in its third year, program participants will receive a $10,000 grant, presented by JPMorgan Chase & Co., and a suite of programmatic support services to assist with international expansion strategies. Program participants will have access to a dedicated staff manager at WTC San Diego, and will receive guidance on export compliance, financing and fundraising, among other international support services.

“We applaud CureMatch for taking the next step in going global,” said Nikia Clarke, executive director of World Trade Center San Diego. “With SMEs like this at the forefront, San Diego must continue to increase its export capacity and boost the region’s global identity. MetroConnect is equipping these companies with the resources necessary to do just that.”

The MetroConnect program is highly competitive, with just 15 selected based on a variety of criteria, including interest in new markets, interest in targeted metro markets, assessed impact of funds, current international traction and more. Applicants were assessed by a panel of judges, including representatives from Qualcomm Ventures, Biocom, UC San Diego, Rough Draft Brewing, San Diego State University, Tech San Diego, U.S. Department of Commerce, UC San Diego, San Diego Regional EDC and WTC San Diego.

CureMatch joins a cohort of 14 other companies representing a unique cross-section of San Diego’s industries, from cleantech to maritime to craft brewing and life sciences – each with plans to take San Diego innovation globally.

Participating companies will also be considered for the program’s MetroConnect Grand Prize Pitchfest in May 2018, which will provide an additional $35,000 to help one or two companies further advance their global agendas.

MetroConnect is underwritten by JPMorgan Chase & Co., with additional support provided by Air Canada, CDC Small Business Finance, Japan Airlines, Japan External Trade Organization, Qualcomm, SYSTRAN, Taylor Guitars and others.

About CureMatch

CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. www.curematch.com.

About World Trade Center San Diego

World Trade Center San Diego operates as an affiliate of San Diego Regional Economic Development Corporation. WTC San Diego works to further San Diego’s global competitiveness by building an export pipeline, attracting and retaining foreign investment and increasing San Diego’s global profile abroad. sandiegobusiness.org/wtcsd

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • CureMatch and Alliance Care Technologies Announce Partnership to Bring Precision Cancer Treatment to More Patients

    CureMatch, Inc., and Alliance Care Technologies International (ACT) have announced a strategic partnership to bring...

  • MedNews: Precision Medicine Clubhouse Presentation with Dr. Kurzrock

    Precision medicine tailors treatments, practices, and products to the specific needs of a patient and...

  • Interview with Dr. Razelle Kurzrock of CureMatch: Why Patients Need Precision Cancer Medicine

    In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder...

  • New Study Validates Payer/Physician Use of AI to Cut Wasteful Spending on High-Cost, Low-Value Cancer Drugs

    The Research Consortium announced the release of a new study today that challenges common misconceptions...

  • CureMatch Names Life Sciences Executive David Szekeres as Board Director

    CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine...

  • CureMatch Appoints Healthcare Executive Dale Brown as Board Director

    CureMatch, Inc., a healthcare technology company that leverages artificial intelligence (AI) to power precision medicine...

  • CureMatch and CureMetrix Align to Support President Biden’s Relaunch of Cancer Moonshot

    In response to President Biden’s relaunch of Cancer Moonshot and his White House commitment to...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (3)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 284-0488

FAX: +1 (858) 430-5813

Quick Links

  • Physicians
  • About CureMatch
  • News and Latest Posts
    • CureMatch News
    • Validation and Case Studies
    • Events and Conferences
  • Contact Us
  • FAQ

Latest News and Results

  • CureMatch and Alliance Care Technologies Announce Partnership to Bring Precision Cancer Treatment to More Patients Jun 21

    CureMatch, Inc., and Alliance Care Technologies International (ACT) have announced a strategic partnership to bring...

  • MedNews: Precision Medicine Clubhouse Presentation with Dr. Kurzrock Jun 8

    Precision medicine tailors treatments, practices, and products to the specific needs of a patient and...

  • Interview with Dr. Razelle Kurzrock of CureMatch: Why Patients Need Precision Cancer Medicine Apr 6

    In this dynamic interview, Chief Medical Advisor, Dr. Kurzrock, sits down with Michelle Morand, Co-Founder...

© 2021 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

We’d like to send you a CureMatch Sample Analysis

 

Sample Analysis Download Form

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data